New eye injection shows promise for Diabetes-Related vision loss
NCT ID NCT05959304
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested the safety and effectiveness of brolucizumab, a drug injected into the eye, for treating diabetic macular edema (DME) in 66 Indian patients. DME is a complication of diabetes that can cause vision loss. The study aimed to see how well the drug works in real-world conditions, not just in controlled trials. Results will help doctors understand if brolucizumab is a good option for managing DME.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
brolucizumab (injected into the eye)
What this could lead to
If successful, this could confirm that brolucizumab is a safe and effective option for managing diabetic macular edema in real-world patients.
What could go wrong
This is a small, completed phase IV study with only 66 participants, so results may not apply to all patients. As with any eye injection, there are risks like infection or inflammation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Ahmedabad, Gujarat, 380052, India
-
Novartis Investigative Site
Bangalore, Karnataka, 560 010, India
-
Novartis Investigative Site
Kochi, Kerala, 682 026, India
-
Novartis Investigative Site
Chennai, Tamil Nadu, 600045, India
-
Novartis Investigative Site
Kolkata, West Bengal, 700 073, India
-
Novartis Investigative Site
Coimbatore, 641002, India
-
Novartis Investigative Site
Kolkata, 700120, India
-
Novartis Investigative Site
New Delhi, 110029, India